Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients

Bickel, Markus; Wieters, Imke; Khaykin, Pavel; Nisius, Gabi; Haberl, Annette; Stephan, Christoph; Hentig, Nils von; Herrmann, Eva; Doerr, Hans Wilhelm; Brodt, H.-R.; Allwinn, Regina

doi:10.1097/qad.0b013e3283398da1

Cited by 62 publications

(51 citation statements)

References 19 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One prospective, observational study found seroconversion (defined as HIA titers ≥40 or ≥4 fold higher after vaccination) in 69% of 160 HIV-infected persons (mean CD4 cell count 523 cells/μL, 90% receiving HAART) after one dose of AS03-adjuvanted influenza A/California/7/2009 (H1N1) vaccine, which was lower than the 79%-98% seroconversion rate reported for the general population [86]. In this study, seroconversion was associated with younger age and higher CD4 cell count.…”

Section: Postexposure Chemoprophylaxis and Ph1n1 Vaccine Among Hiv-inmentioning

confidence: 76%

Influenza and HIV: Lessons from the 2009 H1N1 Influenza Pandemic

2011

View full text Add to dashboard Cite

Influenza is a common respiratory disease in adults, including those infected with HIV. In the spring of 2009, a pandemic influenza A (H1N1) virus (pH1N1) emerged. In this article, we review the existing literature regarding pH1N1 virus infection in HIV-infected adults, which suggests that susceptibility to pH1N1 virus infection and severity of influenza illness are likely not increased in HIV-infected adults without advanced immunosuppression or comorbid conditions. The risk of influenza-related complications, however, may be increased in those with advanced immunosuppression or high-risk comorbid conditions. Prevention and treatment of high-risk comorbid conditions and annual influenza vaccination should continue to be part of HIV clinical care to help prevent influenza illness and complications. Additional information about pH1N1 vaccine immunogenicity and efficacy in HIV-infected patients would be useful to guide strategies to prevent influenza virus infection in this population.

show abstract

Section: Postexposure Chemoprophylaxis and Ph1n1 Vaccine Among Hiv-inmentioning

confidence: 76%

Influenza and HIV: Lessons from the 2009 H1N1 Influenza Pandemic

2011

View full text Add to dashboard Cite

show abstract

“…22,23 In contrast, other work has suggested a lower response in HIV-infected individuals, even in successfully treated patients. [18][19][20] It may be speculated that the apparent discrepancy is mainly attributable to the baseline level of reactivity to influenza virus antigen that is clearly higher in the HIV group.…”

Section: Discussionmentioning

confidence: 99%

“…17 In pandemic A/H1N1 influenza vaccine studies, the data are contrasting. In fact, several studies on the efficacy of MF59-adjuvanted 2009 pandemic A/H1N1 influenza vaccine (A/H1N1/Cal/09) suggested a lower rate of influenza seroconversion in HIV-infected individuals (36.4-69%) as compared with healthy donors ( > 79%), [18][19][20] even in patients with high CD4 T cell counts. 21 In contrast, other studies reported a good antibody response in successfully HAART-treated HIV patients.…”

Section: Introductionmentioning

confidence: 99%

Cellular and Humoral Immune Responses to Pandemic Influenza Vaccine in Healthy and in Highly Active Antiretroviral Therapy-Treated HIV Patients

Agrati

Gioia

Castilletti

et al. 2012

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

“…Für Personen, die noch keinen Kontakt zu Influenzaviren oder -Antigenen hatten und bei denen keine ausreichende Grundimmunität mehr vorausgesetzt werden kann, werden eventuell zwei Impfungen notwendig sein, oder es sind Impfstoffe mit Adjuvanzien vorzuziehen. Wirkstoffverstärkte Grippeimpfstoffe sind gerade für Menschen ab 65 Jahre oder immunsupprimierte Patienten indiziert [4,13].…”

unclassified

Saisonale Influenza-Impfstoffe: Zusammensetzung und Eigenschaften

Allwinn¹,

Doerr²

2011

Dtsch med Wochenschr

View full text Add to dashboard Cite

The influenza virus isolation in embryonated chicken eggs was possible early in 1930er years and allowed the influenza vaccine production. Most influenza vaccines were derived from this, but actually new virus cell culture methods are established. For better tolerability, influenza vaccines include only antigen proportions (split- and subunit vaccines) but with the disadvantage of minor vaccine efficacy. This was compared with the addition of adjuvants. Aluminium salts are used for many decades and still in use to enhance the effect of vaccines. New formulations are MF59, AS03, AS04 or toll- like receptor-agonists. Also virosomal formulations and "ISCOMs"(Immune Stimulating Complexes) are newly designed and compromises enhanced immune reactions. Actually a broad range of various influenza vaccines exist and are available for a very different group of patients (which depends on physical conditions, age, immune status or allergies).

show abstract

Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients

Abstract: Seroconversion after one dose of a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine of HIV-infected patients was 69%. Studies to investigate whether a second dose of the vaccine will increase seroconversion rate are needed.

Cited by 62 publications

References 19 publications

Influenza and HIV: Lessons from the 2009 H1N1 Influenza Pandemic

Influenza and HIV: Lessons from the 2009 H1N1 Influenza Pandemic

Cellular and Humoral Immune Responses to Pandemic Influenza Vaccine in Healthy and in Highly Active Antiretroviral Therapy-Treated HIV Patients

Saisonale Influenza-Impfstoffe: Zusammensetzung und Eigenschaften

Contact Info

Product

Resources

About